{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:21:06Z","timestamp":1788402066750,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92159305"],"award-info":[{"award-number":["92159305"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2023-I2M-2-004"],"award-info":[{"award-number":["2023-I2M-2-004"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFB3203800"],"award-info":[{"award-number":["2022YFB3203800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jconrel.2026.114745","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:07:30Z","timestamp":1772125650000},"page":"114745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapy"],"prefix":"10.1016","volume":"393","author":[{"given":"Xun","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jconrel.2026.114745_bb0005","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114745_bb0010","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future","volume":"21","author":"Christenson","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114745_bb0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1053\/j.gastro.2022.03.056","article-title":"Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment","volume":"163","author":"Wood","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114745_bb0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1758834012453755","article-title":"Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer","volume":"4","author":"Saif","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"18","key":"10.1016\/j.jconrel.2026.114745_bb0025","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114745_bb0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114745_bb0035","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","article-title":"Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer","volume":"178","author":"Ligorio","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114745_bb0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-024-01872-7","article-title":"Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114745_bb0045","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The Immunobiology of the Interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114745_bb0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114745_bb0055","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/j.jconrel.2026.114745_bb0060","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114745_bb0065","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2022.09.010","article-title":"Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy","volume":"30","author":"Yang","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"8","key":"10.1016\/j.jconrel.2026.114745_bb0070","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.7150\/thno.39434","article-title":"Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs","volume":"10","author":"Qiao","year":"2020","journal-title":"Theranostics"},{"issue":"Suppl. 9","key":"10.1016\/j.jconrel.2026.114745_bb0075","doi-asserted-by":"crossref","first-page":"S1406","DOI":"10.21037\/tcr.2017.10.32","article-title":"Therapeutic targeting of oncogenic KRAS in pancreatic cancer by engineered exosomes","volume":"6","author":"Whiteside","year":"2017","journal-title":"Transl. Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114745_bb0080","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1021\/acs.nanolett.1c00094","article-title":"Natural or synthetic RNA delivery: a stoichiometric comparison of extracellular vesicles and synthetic nanoparticles","volume":"21","author":"Murphy","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2026.114745_bb0085","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114745_bb0090","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70985","article-title":"Current status of research on losartan in tumour therapy","volume":"30","author":"Wang","year":"2026","journal-title":"J. Cell. Mol. Med."},{"issue":"384","key":"10.1016\/j.jconrel.2026.114745_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8504","article-title":"Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis","volume":"9","author":"Vennin","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"36","key":"10.1016\/j.jconrel.2026.114745_bb0100","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase Ib\/II study of gemcitabine plus placebo or Vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2026.114745_bb0105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","article-title":"A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma","volume":"45","author":"Ko","year":"2016","journal-title":"Pancreas"},{"key":"10.1016\/j.jconrel.2026.114745_bb0110","doi-asserted-by":"crossref","first-page":"iv117","DOI":"10.1093\/annonc\/mdv262.02","article-title":"LBA-02 high response rate and PFS with PEGPH20 added to nab-paclitaxel\/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: interim results of a randomized phase 2 study","volume":"26","author":"Hendifar","year":"2015","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.jconrel.2026.114745_bb0115","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus Pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114745_bb0120","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114745_bb0125","doi-asserted-by":"crossref","first-page":"F278","DOI":"10.1152\/ajprenal.00139.2003","article-title":"Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1","volume":"286","author":"Naito","year":"2004","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114745_bb0130","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ekir.2023.02.1092","article-title":"Quantitative blood oxygenation level dependent magnetic resonance imaging for estimating intra-renal oxygen availability demonstrates kidneys are hypoxemic in human CKD","volume":"8","author":"Prasad","year":"2023","journal-title":"Kidney Int. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114745_bb0135","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/schbul\/sbab111","article-title":"Quantifying retinal microvascular morphology in schizophrenia using swept-source optical coherence tomography angiography","volume":"48","author":"Bannai","year":"2022","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jconrel.2026.114745_bb0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-physiol-021119-034627","article-title":"The acidic tumor microenvironment as a driver of cancer","volume":"82","author":"Boedtkjer","year":"2020","journal-title":"Annu. Rev. Physiol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.114745_bb0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3110","article-title":"Dysregulated pH: a perfect storm for cancer progression","volume":"11","author":"Webb","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114745_bb0150","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1021\/acs.molpharmaceut.6b00929","article-title":"Biodistribution of self-assembling polymer\u2013gemcitabine conjugate after systemic administration into orthotopic pancreatic tumor bearing mice","volume":"14","author":"Kattel","year":"2017","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114745_bb0155","first-page":"299","article-title":"Distribution of gemcitabine is nearly homogenous in two orthotopic murine models of pancreatic cancer","volume":"30","author":"Kramer","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"issue":"35","key":"10.1016\/j.jconrel.2026.114745_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303835","article-title":"Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy","volume":"35","author":"Tang","year":"2023","journal-title":"Adv. Mater."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114745_bb0165","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/annonc\/mdy076","article-title":"Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors","volume":"29","author":"Italiano","year":"2018","journal-title":"Ann. Oncol."},{"issue":"10054","key":"10.1016\/j.jconrel.2026.114745_bb0170","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.114745_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216859","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: challenges and opportunities","volume":"591","author":"Qin","year":"2024","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114745_bb0180","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.jconrel.2026.114745_bb0185","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/MPA.0000000000000125","article-title":"Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma","volume":"43","author":"Kim","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.jconrel.2026.114745_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for cancer immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114745_bb0195","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","article-title":"Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours","volume":"4","author":"Mansurov","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114745_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102350","article-title":"Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer","volume":"35","author":"Hughson","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"16","key":"10.1016\/j.jconrel.2026.114745_bb0205","doi-asserted-by":"crossref","first-page":"20012","DOI":"10.1021\/acsami.3c02934","article-title":"Multifaceted Nano-DEV-IL for sustained release of IL-12 to avert the immunosuppressive tumor microenvironment and IL-12-associated toxicities","volume":"15","author":"Barnwal","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.114745_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139302","article-title":"Interaction between interleukin-12 (IL-12) and its receptor (IL-12R\u03b22) mediates CD4(+) T cell subsets activation in flounder (Paralichthys olivaceus)","volume":"293","author":"Wu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114745_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301969","article-title":"Automatic quantification of tumor-stroma ratio as a prognostic marker for pancreatic cancer","volume":"19","author":"Vendittelli","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114745_bb0220","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.jconrel.2026.114745_bb0225","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2023.41.16_suppl.2520","article-title":"A phase 1\/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors","volume":"41","author":"Ji","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"505","key":"10.1016\/j.jconrel.2026.114745_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114745_bb0235","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tranon.2016.07.004","article-title":"Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma","volume":"9","author":"Kumar","year":"2016","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.jconrel.2026.114745_bb0240","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114745_bb0245","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-0716-0327-7_17","article-title":"EPIC: a tool to Estimate the proportions of different cell types from bulk gene expression data","volume":"2120","author":"Racle","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"21","key":"10.1016\/j.jconrel.2026.114745_bb0250","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2026.114745_bb0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"issue":"12","key":"10.1016\/j.jconrel.2026.114745_bb0260","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926001471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:04:14Z","timestamp":1781715854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"alternative-id":["S0168365926001471"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114745","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Losartan primes pancreatic tumors for effective exosome-biomimetic chemo-immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114745"}}